A Phase 3 interventional study of eteplirsen in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 37 sites in United States. Open to male participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 3, and was the 5th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 16 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2014.
This study's enrollment of 109 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 4th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).
This is an open-label, multi-center study to evaluate the efficacy and safety of eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to exon 51 skipping (treated group), with a concurrent control arm of DMD patients not amenable to exon 51 skipping (untreated group). Following primary efficacy endpoints, dosing will continue to week 144 to evaluate the long term effects of eteplirsen.
Patients in the treated group will receive once weekly intravenous (IV) infusions of 30 mg/kg Eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks). Patients in the untreated group will not receive treatment.
Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as the six minute walk test. Patients in the treated group will undergo a muscle biopsy at Baseline and a second muscle biopsy over the course of the study. Patients in the untreated group will not undergo muscle biopsy.
Safety, including adverse event monitoring and routine laboratory assessments, will be continuously monitored for all patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Drug: eteplirsen
Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Also known as: AVI-4658, EXONDYS 51®
Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 96 was reported.
Time frame: Baseline, Week 96
Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96
Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.
Time frame: Baseline, Week 96
Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96
NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. For all activities, participants were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. Number of participants having ability to rise independently from the floor indicated by a NSAA Rise from floor sub score greater than 0 (unable to achieve goal independently) was reported.
Time frame: Week 96
Number of Participants Who Lost Ambulation (LOA) by Week 96
Number of participants who lost ambulation (LOA) by Week 96 was reported. Participant were considered non-ambulatory if each of the 3 conditions below were met: NSAA walk subscore was "0" (unable to achieve goal independently) on 2 consecutive days within a visit or NSAA was not done due to reason related to non-ambulation; 6MWT was not done with any reason related to permanent non-ambulation; and no later data showing this participant was still ambulatory. This was not required if non ambulatory status occurred at the time of early withdrawal or at the end of Week 96 assessment. NSAA is a 17-item scale to assess the participant's abilities; total score range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.
Time frame: Up to Week 96
Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry; and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent of predicted FVC = (observed value) / (predicted value) \* 100%.
Time frame: Baseline, Week 96
Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96
NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participant were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. NSAA total score was derived by summing the scores for all the individual items and range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.
Time frame: Baseline, Week 96
Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96
Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.
Time frame: Baseline, Week 96
The study was conducted at 40 sites in the United States.
| Milestone | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Started | 79 | 30 |
| Completed | 78 | 15 |
| Not completed | 1 | 15 |
| Withdrew: Participants enrolled into another study | 0 | 11 |
| Withdrew: Withdrawal by subject | 1 | 4 |
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 96 was reported.
| meters | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96 | -117.91 ± 128.488 | -133.56 ± 129.333 |
Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.
| Percent Normal Dystrophin Protein Level | Eteplirsen 30 mg/kg |
|---|---|
| Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96 | 0.516 ± 0.7236 |
NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. For all activities, participants were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. Number of participants having ability to rise independently from the floor indicated by a NSAA Rise from floor sub score greater than 0 (unable to achieve goal independently) was reported.
| Participants | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96 | 33 | 3 |
Number of participants who lost ambulation (LOA) by Week 96 was reported. Participant were considered non-ambulatory if each of the 3 conditions below were met: NSAA walk subscore was "0" (unable to achieve goal independently) on 2 consecutive days within a visit or NSAA was not done due to reason related to non-ambulation; 6MWT was not done with any reason related to permanent non-ambulation; and no later data showing this participant was still ambulatory. This was not required if non ambulatory status occurred at the time of early withdrawal or at the end of Week 96 assessment. NSAA is a 17-item scale to assess the participant's abilities; total score range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.
| Participants | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Number of Participants Who Lost Ambulation (LOA) by Week 96 | 12 | 1 |
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry; and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent of predicted FVC = (observed value) / (predicted value) \* 100%.
| Percentage of predicted FVC | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96 | -3.413 ± 12.4011 | -2.461 ± 9.6000 |
NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participant were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. NSAA total score was derived by summing the scores for all the individual items and range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.
| Unit on scale | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96 | -7.23 ± 5.173 | -8.44 ± 9.812 |
Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.
| Percent dystrophin positive fibers | Eteplirsen 30 mg/kg |
|---|---|
| Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96 | 0.030 ± 0.0360 |
Collected over From start of study drug administration to Week 144. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eteplirsen 30 mg/kg | 0/79 (0%) | 11/79 (13.9%) | 78/79 (98.7%) |
| Untreated Control Group (Non-exon 51 Amenable Participants) | 0/30 (0%) | 2/30 (6.7%) | 24/30 (80%) |
| Event | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| AbasiaGeneral disorders | 0/79 | 1/30 |
| Lymphadenitis viralInfections and infestations | 0/79 | 1/30 |
| Femoral neck fractureInjury, poisoning and procedural complications | 2/79 | 0/30 |
| Femur fractureInjury, poisoning and procedural complications | 1/79 | 0/30 |
| Hip fractureInjury, poisoning and procedural complications | 1/79 | 0/30 |
| Pneumonitis chemicalInjury, poisoning and procedural complications | 1/79 | 0/30 |
| ArrhythmiaCardiac disorders | 1/79 | 0/30 |
| MyocarditisCardiac disorders | 1/79 | 0/30 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/79 | 0/30 |
| AspirationRespiratory, thoracic and mediastinal disorders | 1/79 | 0/30 |
| Event | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) |
|---|---|---|
| HeadacheNervous system disorders | 40/79 | 1/30 |
| VomitingGastrointestinal disorders | 39/79 | 0/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/79 | 1/30 |
| Back painMusculoskeletal and connective tissue disorders | 29/79 | 1/30 |
| NasopharyngitisInfections and infestations | 29/79 | 3/30 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 26/79 | 2/30 |
| Procedural painInjury, poisoning and procedural complications | 25/79 | 0/30 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 25/79 | 1/30 |
| Upper respiratory tract infectionInfections and infestations | 25/79 | 1/30 |
| ContusionInjury, poisoning and procedural complications | 24/79 | 1/30 |
Consisted of all participants who received at least 1 dose of eteplirsen in the eteplirsen-treated group or had at least 1 post-baseline safety assessment in the untreated group.Comparisons between the eteplirsen-treated and the untreated group were not to be performed due to the small number of subjects and differences in the population groups.
| Age, Continuous(Years) | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Mean | 9.1 ± 2.04 | 8.8 ± 1.76 | 9.0 ± 1.96 |
| Sex: Female, Male(Participants) | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 79 | 30 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 13 |
| Not Hispanic or Latino | 71 | 24 | 95 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 2 | 0 | 2 |
| White | 67 | 26 | 93 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Region of Enrollment(Participants) | Eteplirsen 30 mg/kg | Untreated Control Group (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| United States | 79 | 30 | 109 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2014 to primary completion in Jun 2019, 54 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 54 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →